ClinicalTrials.Veeva

Menu

Prognostic Factors for Treatment Responses in Patients With Active Lupus Nephritis at Sohag University Hospital

S

Sohag University

Status

Unknown

Conditions

We Aim to Examine the Predictors of Sustained Complete Renal Remission in Patients With Lupus Nephritis at Sohag University Hospital

Treatments

Drug: sandimmun

Study type

Observational

Funder types

Other

Identifiers

NCT04756492
Soh-Med-21-02-06

Details and patient eligibility

About

Systemic lupus erythematosus (SLE) is an autoimmune disease which may give rise to multiple organ involvement because of immune complex deposits. Lupus nephritis (LN) is one of the severe manifestations of systemic lupus erythematous (SLE) and a common cause for end-stage renal disease, significantly affecting the survival of SLE patients Immunosuppressive treatment is the major therapy for active LN. Generally, at least six months are needed to assess treatment responses Failure to respond to immunosuppressive therapy can lead to a worsening of renal function

Full description

This study will be prospectively analyzing the clinical data of LN patients who received standard immunosuppressive therapy and were regularly followed up at our center for more than six months. These patients will not change treatment regimen during the six months.

As remission is an independent predictor of good long term prognosis in lupus nephritis. We aim to examine the predictors of sustained complete renal remission in patients with lupus nephritis at Sohag University Hospital and to analyze data of lupus nephritis patients to find parameters that can predict remission and improve outcome of our cases

Enrollment

100 estimated patients

Sex

All

Ages

14 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • o Patients diagnosed with LN at Sohag University Hospital

    • Patients in regular follow-up for more than six months after immunosuppressive therapy
    • Baseline urinary protein/creatinine ratio (UPCR) more than 1 g/g
    • Baseline C3 less than 55 mg/ dl
    • No change in immunosuppressive therapy within six months

Exclusion criteria

  • o Patients with incomplete pathological data and the number of glomeruli being <10 per biopsy specimen

    • Age <14 years old End-stage renal disease (ESRD) status on admission (sustained estimated glomerular filtration rate (eGFR) <15 ml/min per 1.73m2)
    • Patients with advanced comorbid conditions like advanced liver cirrhosis or heart failure or malignancy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems